Brief: Abbisko Cayman Unit's CSF-1R Inhibitor Gets Phase III Trial Approval From China's NMPA
24/10/2022 23:15
Oct 25 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* CSF-1R INHIBITOR ABSK021 OF UNIT GRANTED PHASE III
CLINICAL
TRIAL APPROVAL BY CHINA'S NMPA
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration